TY  - JOUR
TI  - Non-alcoholic Fatty Liver Disease and Its Association with Serum Nesfatin- 1
AB  - Aim: Nesfatin -1 is a novel peptide which is defined as satiety peptide with an anorexigenic action. Studies have shown its association with metabolic syndrome and insulin resistance. With this study, we sought to establish the association between clinicopathologic characteristics of patients with biopsy-diagnosed non-alcoholic fatty liver disease (NAFLD) and Nesfatin-1. Materials and Methods: Serum Nesfatin-1 levels were measured using the enzyme-linked immunosorbent assay in 59 patients with histologically diagnosed NAFLD and a control group comprising 32 healthy subjects. Results: Serum Nesfatin-1 level did not significantly differ between patients with NAFLD and control group (p<0.170). Simple correlation analysis showed that nesfatin-1 levels decreased as body mass index increased (p=0.043) and nesfatin-1 values increased in proportion to elevations in AST (p=0.05). A multiple regression model constructed for assessment showed that while portal inflammation (B=10.767, p=0.007), body mass index score (B=-0.510, p<0.001) and HDL cholesterol (B=-0.208, p<0.001) had a negative association with nesfatin-1, age (B=0.120, p=0.031), sex (lower levels among males versus females) (B=-40.897, p<0.001), systolic blood pressure (B=0.063, P=0.050) and AST (B=0.033, p=0.019) had a positive and linear significant association with nesfatin-1. Conclusion: In conclusion, the findings point out that serum nesfatin-1 level may be an independent predictor of portal inflammation in NAFLD.
AU  - Arikan, Sener
AU  - ORAL, HALUK BARBAROS
AU  - DOLAR, M.ENVER
AU  - ayyıldız, talat
AU  - Balaban Adım, Şaduman
DO  - 10.21673/anadoluklin.824294
PY  - 2021
JO  - ANADOLU KLİNİĞİ TIP BİLİMLERİ DERGİSİ
VL  - 26
IS  - 1
SN  - 2149-5254
SP  - 45
EP  - 53
DB  - TRDizin
UR  - http://search/yayin/detay/1151362
ER  -